Table 2.
Molecular characteristics and follow-up of male breast cancer patients.
| Characteristics | Number | Number (%) |
|---|---|---|
| Germline BRCA2 mutations | 37 | |
| Indeterminate | 25 (67.6%) | |
| Positive | 12 (32.4%) | |
| Estrogen receptor (ERα) status | 128 | |
| Positive | 125 (97.7%) | |
| Negative | 3 (2.3%) | |
| Progesterone receptor (PR) status | 120 1 | |
| Positive | 97 (81%) | |
| Negative | 23 (19%) | |
| ERBB2 (IHC and ISH) status | 120 1 | |
| Negative | 111 (92.5%) | |
| Positive | 9 (7.5%) | |
| Ki67 immunoreactivity | 120 1 | |
| Low | 77 (64.2%) | |
| High | 43 (35.8%) | |
| Clinically defined subtypes | 120 1 | |
| Luminal A-like | 44 (36.7%) | |
| Luminal B-like | 64 (53.3%) | |
| HER2-like | 9 (7.5%) | |
| Triple negative | 3 (2.5%) | |
| Follow-up | 128 | |
| Died of disease | 40 (31.3%) |
1 Excluding eight in situ carcinomas.